cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Biomea Fusion Inc
2 own
6 watching
Current Price
$9.53
$0.11
(1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
280.07M
52-Week High
52-Week High
14.2
52-Week Low
52-Week Low
2.84
Average Volume
Average Volume
0.06M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization280.07M
icon52-Week High14.2
icon52-Week Low2.84
iconAverage Volume0.06M
iconDividend Yield--
iconP/E Ratio--
What does the Biomea Fusion Inc do?
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Read More
How much money does Biomea Fusion Inc make?
News & Events about Biomea Fusion Inc.
Globe Newswire
18days ago
BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)A pan-KRAS inhibitor targeting multiple KRAS mutations (including G12C, G12D and G12R, among others) has ...
Globe Newswire
26days ago
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic ...
Globe Newswire
1month ago
COVALENT-111,now underway in the US, has completed Phase I and is currently enrolling type 2 diabetes patients in the Phase II randomized, placebo-controlled portion of the trialBMF-219, an orally available covalent menin inhibitor, is being evaluated for its potential to enable the proliferation, ...
Globe Newswire
1month ago
BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Picomolar affinity to activating FLT3 mutations including FLT3-ITD and various tyrosine kinase domain (TKD) mutationsMulti-fold higher potency and increased cytotoxicity than commercially available non-...
Globe Newswire
2 months ago
REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and ...
Frequently Asked Questions
Frequently Asked Questions
What is Biomea Fusion Inc share price today?
plus_minus_icon
Can Indians buy Biomea Fusion Inc shares?
plus_minus_icon
How can I buy Biomea Fusion Inc shares from India?
plus_minus_icon
Can Fractional shares of Biomea Fusion Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Biomea Fusion Inc stocks?
plus_minus_icon
What is today’s traded volume of Biomea Fusion Inc?
plus_minus_icon
What is today’s market capitalisation of Biomea Fusion Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Biomea Fusion Inc?
plus_minus_icon
What percentage is Biomea Fusion Inc down from its 52-Week High?
plus_minus_icon
What percentage is Biomea Fusion Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.53
$0.11
(1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00